PAR 3.23% 30.0¢ paradigm biopharmaceuticals limited..

research reports and media, page-2502

  1. 184 Posts.
    lightbulb Created with Sketch. 40
    Spot on greed, any partnership deal will most likely be valued based of the current Market Cap, so even if they go down the partnership route the valuation will be significantly less than the price on the Phase III approval news.

    Also all this talk by PR about protection against a hostile takeover is laughable. If there had been approaches you would think management would inform the market of this, at least that would be a positive catalyst to the share price.

    They need this new CEO yesterday and until these funding issues are rectified the price will continue to come under pressure.

    DYOR
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
30.0¢
Change
-0.010(3.23%)
Mkt cap ! $104.9M
Open High Low Value Volume
31.0¢ 31.5¢ 29.0¢ $161.3K 527.5K

Buyers (Bids)

No. Vol. Price($)
2 10756 30.0¢
 

Sellers (Offers)

Price($) Vol. No.
31.0¢ 62010 3
View Market Depth
Last trade - 16.10pm 15/07/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.